Arden Barry

Pharmacist Clinician-Researcher in Cardiology | Associate Professor (Partner) @ubcpharmacy | Editorial Board @CPJ_RPC @CJCJournals | #cardiotwitter #TwitteRx

[Arden Barry @ArdenBarry]

The FDA has approved the first oral PCSK9 inhibitor, enlicitide, to lower LDL-C in patients with hypercholesterolemia. https://t.co/63fIz785LA

[Arden Barry @ArdenBarry]

Congratulations, Jim!

[ACCP Cardiology PRN @accpcardprn]

Congratulations to Dr. Jim Coons on being selected for this year’s ACCP PRN Seed Grant for his project titled “Selexipag treatment persistence and pharmacogenomics.” We look forward to seeing how your research impacts the care of PAH patients!

[ACCP Cardiology PRN @accpcardprn]

It’s #TBT! Going back to 2004 with the Camelot trial, the first major trial that showed lowering blood pressure slows down atherosclerosis progression. Thank you to PGY1 Resident Maryam Alarfaj for making this infographic! #cardiotwitter

[ACCP Cardiology PRN @accpcardprn]

The Card PRN has a new website: https://t.co/6IbqQc35Fa

This PRN member-exclusive platform was designed to allow members to connect with colleagues across the various cardiology Rx subspecialties. There are two new subcommunities: antithrombotic management and heart failure.

[Arden Barry @ArdenBarry]

Our contemporary practice tool to assist #pharmacists in managing patients with heart failure now published in @CPJ_RPC #heartfailure #cardiotwitter https://t.co/BAbjXFfK7A

[ACCP Cardiology PRN @accpcardprn]

Happy #TBT! This week, we revisit CLEAR Outcomes, published in @NEJM almost exactly 3 years ago. This was the first CV outcome trial with bempedoic acid in patients with statin intolerance. Thanks to 🇨🇦 PGY1 #pharmacy resident @Arjun_Kandola for this infographic. #cardiotwitter

[ACCP Cardiology PRN @accpcardprn]

It's another #TBT! 🙏 to Heidi Gonzalez Ramirez of @umsop for revisiting the AURORA trial in this infographic. 💊

AURORA was the first large-scale international trial to assess the effects of statins on CV outcomes in patients with ESRD on HD. #cardiotwitter

[Arden Barry @ArdenBarry]

@Gladwell You should do a Revisionist History episode about this story. The story is based in Toronto and, as you say, it is absolutely bananas.

[The New Yorker @NewYorker]

A paper by a renowned toxicologist argued for the first case of opioid overdose by breast milk in history. But in the years that followed, researchers began to suspect that the science was bunk. https://t.co/JvWEg3hUpZ

[Arden Barry @ArdenBarry]

Higher medication optimization score was associated with lower all-cause mortality or hospitalization in patients with HFrEF. Algorithm can identify patients who may benefit from medication optimization. #CardioTwitter #heartfailure #pharmacists

[Pharmacotherapy @PharmacoJournal]

This algorithm that generates medication optimization scores effectively identifies opportunities for guideline-directed medication therapy optimization in real-world clinical settings. OPEN ACCESS: https://t.co/GWvx7bHocY

[Arden Barry @ArdenBarry]

Our study of patients' perceptions of #pharmacist prescribing for the minor ailments and contraception service (MACS) in BC 🇨🇦 published @JACCPJournal https://t.co/2rkvOFbaxj

[Arden Barry @ArdenBarry]

#Pharmacists’ experience with automated external defibrillators #AED @CPJ_RPC https://t.co/Lu9Bi9S25D

[Arden Barry @ArdenBarry]

The landscape of automated external defibrillators in #pharmacies #AED @CPJ_RPC https://t.co/Q7kw01H37n

[Arden Barry @ArdenBarry]

Literature review of #pharmacies and automated external defibrillators #AED @CPJ_RPC https://t.co/Y1I4xhRMoc

[Arden Barry @ArdenBarry]

Should all #pharmacies have an automated external defibrillator? #AED @CPJ_RPC https://t.co/jtrJHlF7AG

[Arden Barry @ArdenBarry]

I'm grateful for the opportunity to have been a guest editor and work with @Ross_Tsuyuki on this supplement dedicated to automated external defibrillators in #pharmacies in @CPJ_RPC. #AED #cardiacarrest https://t.co/P1TcB8wSrE

[ACCP Cardiology PRN @accpcardprn]

It's #TBT! This week, we're revisiting the innovative LA Barbershop Study, where #pharmacist-led management of #hypertension at Black barbershops resulted in an impressive SBP reduction. Thanks to @BetCloPharmD at @UNCHealthRex for making this infographic. #CommunityHealth

[ACCP Cardiology PRN @accpcardprn]

For #TBT, we're going back to 2016 for the HOPE-3 trial. Fixed-dose, moderate-intensity rosuvastatin lowered the risk of MACE in patients at intermediate CV risk. TY to Dr. Emily Mattarollo, who was a @lmpsresidency PGY1 resident in 🇨🇦, for creating this infographic!

[ACCP Cardiology PRN @accpcardprn]

Happy #WNW on Thanksgiving eve! The JCF recently published a subgroup analysis of the ARIES-HM3 trial. It appears that neither afib, DM, or obesity altered the results of the trial, with ASA avoidance appearing both safe and effective on HM3 patients!

https://t.co/JxYJhqpA3d

[ACCP Cardiology PRN @accpcardprn]

It’s #whatsnewwednesday! Does your team still debate warfarin v DOAC for LV thrombus? A Meta-Analysis of RCTs indicates no difference based on available data. Now the next conundrum - do you load the DOAC or start maintenance dosing? https://t.co/FgwKez5IN7

[ACCP Cardiology PRN @accpcardprn]

For #TBT, we're revisiting the ACCOMPLISH trial. In pts with #hypertension at high CV risk (60% T2D), combo of ACEI+DHP CCB reduced CV events vs ACEI+thiazide. TY Dr. Sarah Burke, PGY1 resident with @lmpsresidency in Vancouver #YVR 🇨🇦, for making this infographic. #cardiotwitter